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Machine learning is the subject of a large and sophisticated professional literature, 
with excellent books for biomedical engineers [1, 2] as well as at least one excellent text 
available free online [3]. Machine learning, together with related topics such as data 
mining, provides a set of tools with a huge potential range of applications from improv-
ing medical diagnosis to optimization of cancer therapy. It has also been the subject of 
considerable hype in the popular literature.
The first part of this commentary reviews an introduction to machine learning, 
“Master Machine Learning Algorithms” which is subtitled “Discover How They Work 
and Implement Them From Scratch”. The author, Jason Brownlee, aims to introduce 
readers to practical use of machine learning. On his website (http://machinelearning-
mastery.com/about/) Brownlee describes himself as a software developer who initially 
taught himself machine learning “to figure this stuff out”. He also is an active blogger on 
machine learning, and has written several books on the topic for novices, some available 
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online at his website and others available through online stores such as Amazon. In a 
sense, Brownlee is one of us, with a Ph.D. (Swinburne University, Melbourne, Australia) 
and a thesis and academic publications on modeling of artificial immune systems.
Master Machine Learning Algorithms can be purchased online at https://machine-
learningmastery.com/master-machine-learning-algorithms/ (accessed on 03.08.2017) at 
modest cost ($USD 37), which also includes 17 Excel spreadsheets to illustrate the main 
algorithms. His website offers 10 related books (including four at a more advanced level) 
that are tailored for use with the statistical program such as R or the data mining pro-
gram Weka (both freely distributed on the internet). So, for very little money, a reader 
can have a useful basic introduction to the topic together with ready-made software to 
play around with. Brownlee frequently sends emails to a wide distribution list with inter-
esting tutorial material about topics in machine learning.
In the 162 pages of the version presently being reviewed, Brownlee describes 11 basic 
machine learning algorithms and implements them in Excel spreadsheets, in a rudimen-
tary but informative way. For each algorithm, the author describes the underlying math-
ematics, and for most of them he provides a tutorial with links to an Excel spreadsheet 
and graphs and tables with results. The book is divided roughly into three parts: lin-
ear algorithms (pages from 25 to 71), nonlinear algorithms (pages from 72 to 125), and 
ensemble algorithms (pages from 126 to 149). The algorithms discussed include linear 
regression, logistic regression, discriminant analysis, classification and regression trees, 
Naive Bayes, k-nearest neighbours, support vector machines, decision trees. Introduc-
tory and concluding chapters discuss general aspects of machine learning, including 
problems of overfitting.
Obviously, this book is not competitive with other well-known introductions to 
machine learning for professionals [1–3], nor is it intended to be. In spirit, it is a bit like 
the introductory book on French cooking entitled Je Ne Sais Pas Cuisiner (“I don’t know 
how to cook”) (Flammarion, 1997)—a collection of recipes and rudimentary instructions 
for novice cooks but hardly competition for Escoffier or even Julia Child. However, it is 
very clearly written and for what it tries to accomplish it succeeds well.
Fig. 1 Graph of dependence of accuracy (ACC) for 1000 drawings of data for learning and test vector for 
different classifiers
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We continue with a more detailed review of the book, and conclude with a commen-
tary on some of the larger issues that are involved in applying machine learning and data 
mining to biomedical problems.
Where it succeeds
The book nicely fills the gap between popular oriented, often hyperbolic introductions 
to machine learning for laypeople, and textbooks for professionals. To a novice enter-
ing the field, it is highly educational to use the tools of machine learning as provided in 
Microsoft Excel spreadsheets and trace their operation step by step. Unlike other intro-
ductions to machine learning [3–6], the reader does not need to buy expensive software 
such as Matlab or grapple with complicated software such as R and Weka which are ref-
erenced in other versions of this book. This approach has great merit as an introduction 
to a challenging subject that requires a low initial investment. It is a bit like introducing 
elementary school students to music by teaching them to play inexpensive recorders: 
the lessons can instil a lifelong appreciation of music but nobody pretends to turn the 
kids into musicians. This book will not “make developers awesome at machine learning” 
as Brownlee’s slogan in his email signature says. Rather, it is a “gentle introduction” (his 
expression) to a complex field, and is very suitable for helping high school and under-
graduate university students get off to a good start with these methods.
Where it is lacking
For professional use, the major limitation is lack of depth. The 227 word section entitled 
“how to limit overfitting” mentions standard techniques such as k-fold cross validation, 
but does not explain how to do it properly. Each algorithm is described in 3–4 pages that 
are clearly written but lack mathematical detail.
Moreover, the educational value of the book is stymied by a complex programming 
style in the Excel spreadsheets that will be very hard for novices to follow and adapt 
to their own problems. For example, cell (173, J) in the spreadsheet 14-SupportVec-
torMachine.xlsx contains the statement:  =  IF($H173  <  1;((1  −  $E173)*G173  +  (1/
($A$17*$A173))* $D173* C173);((1 − $E173)*G173))”. The book would be more useful 
if it the spreadsheets were more easily adapted to other problems. A simpler, if less com-
pact, programming style would enhance the tutorial values of the spreadsheets, as would 
a closer tie of the spreadsheets to the mathematics in the background discussion.
The larger problem
Machine learning and data mining techniques can discover previously unknown regu-
larities in data and make useful predictions. But finding regularities in an existing set of 
data and making useful predictions about data collected in the future are two different 
things. If we could learn patterns in stock market data and use them to successfully pre-
dict the future prices of stock we would all be rich. Building models for use in medicine 
raises further complications in meeting the needs of physicians and their patients. The 
following discussion pertains equally to machine learning and data mining, which are 
closely related.
At the technical level, machine learning and data mining algorithms are now included 
in numerous software packages and are very easy to use. However, they can be unreliable 
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in the hands of naïve practitioners—just the people to whom this volume is addressed. 
The problem is that they provide great flexibility in analysis at the cost of interpretability, 
and thus appear as “black boxes” to an unsophisticated user.
Two problems in particular can easily trip up a novice: overfitting and leakage. Over-
fitting refers to the tendency of overly complex models to “learn” noise resulting in loss 
of generalizability (a simple example is fitting a set of data to a high-level polynomial). 
Leakage occurs when the user inadvertently carries information from the training set 
(used to train the classifier) to the test set (used to validate the classifier).
Brownlee gives helpful advice about overfitting in several places but does not make it 
clear how subtle the problem can be. Brownlee does not discuss leakage in this book, 
although he provides insightful discussions of the problem in his blog (http://machine-
learningmastery.com/data-leakage-machine-learning/); an extensive professional lit-
erature exists on the subject (e.g. Kaurman 2012). A common novice error is to tune a 
classifier to obtain the “best” results, but continue to use the same test data—which con-
sequently invalidates its statistical independence and makes it unreliable for validation 
purposes. There are, of course, many discussions of these problems in the professional 
literature but these are more advanced sources than this present volume.
A different set of problems arise with developing sophisticated statistical methods 
for use in clinical medicine. These need to work at the technical level that is familiar to 
engineers, and also meet the needs of doctors and patients. A quick search on Google 
Scholar will uncover hundreds of papers that use machine learning or data mining to 
develop methods to diagnose disease, estimate a patient’s prognosis from a disease, or 
another purpose. The projects range from, at the high end, a handful of large studies 
supported by companies such as Google and Apple, to a great many much smaller stud-
ies by engineers from around the world. A large fraction of these papers are published 
in engineering and computer science journals as opposed to practice-oriented medical 
journals, and are clearly aimed at other engineers.
Developing useful clinical tests using machine learning
A useful perspective is provided in the widely-cited 1991 paper by Fryback and Thorn-
bury on the efficacy of diagnostic imaging. While the article focuses on diagnostic imag-
ing, similar considerations apply to a wide range of other medical applications.
Fryback and Thornbury emphasize that the medical value of a diagnostic test needs to 
be assessed on several levels: (1) the technical level; (2) its diagnostic accuracy measured 
in terms of sensitivity and specificity; (3) its contribution to changing the diagnostic 
thinking of a physician; (4) its contribution to developing a patient’s management plan; 
(5) its contribution to improving the patient’s outcome; and (6) the societal costs and 
benefits of the test.
We consider two examples: machine learning/data mining to diagnose coronary artery 
disease, and for estimating prognosis of survival from breast cancer. Numerous papers 
are easily located on Google Scholar on these topics, a large fraction of which appeared 
in engineering or computer science journals. We describe databases that have been used 
for such purposes. Our goal is not to criticize the studies, but to point to the differences 
in scale of data needed to develop an algorithm and in establishing its clinical efficacy for 
real-world medical use.
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Two datasets, available online, have been used to develop algorithms for diagnosis of 
coronary artery disease (CAD). One is the “Z-Alizadeh” dataset [7] that consists of 55 
different clinical parameters, demographic data and results of medical tests measured in 
303 patients that were collected from random visitors to a Tehran cardiology center. A 
second dataset is “heart” (http://www-bcf.usc.edu/~gareth/ISL/data.html), that has 13 
attributes from 303 patients from an unknown medical center. This latter data set has 
been used in an extensive case study in the James’s textbook [3].
Both datasets raise interesting technical issues. They are both unbalanced (unequal 
numbers of healthy and diseased subjects) and contain a mix of qualitative and quantita-
tive data. Both datasets have too many attributes relative to the number of subjects and 
must be pruned (choosing a subset of attributes for the classifier). James et al. [3] and 
Alizadehsani [7] both give excellent discussions of the pruning process, one from the 
perspective of a research paper and the second from a didactic perspective. One of the 
attributes in the “heart” data set is the result of the thallium stress test, which is a diag-
nostic test for CAD. Not surprisingly, James et al. [3] show that this attribute has by far 
the greatest importance in training a classifier for diagnosis of CAD.
The second example is prognosis of breast cancer survival. Several papers 
use the Haberman Survival dataset (http://archive.ics.uci.edu/ml/datasets/
Haberman’s+Survival), that contains the 5-year survival status of 306 patients who had 
undergone breast cancer surgery. The data set has two classes (alive or dead 5 years after 
surgery) and three attributes (age of patient at time of operation, year of patient’s opera-
tion, and the number of positive axilliary nodes detected). This data set is also inter-
esting as a didactic example of machine learning for binary classification, and has been 
discussed by one expert as a particularly difficult problem in binary classification [8] (For 
comments on that see Appendix and Additional file  1). However, it lacks information 
such as grade of the tumor and data about hormone sensitivity and use of any adjuvant 
therapy (such as chemotherapy after surgery) that would be needed for accurate prog-
nosis. The data set is also unbalanced (most of the patients were still alive after 5 years) 
and it has too few attributes to benefit from the distinctive benefits of machine learning, 
which is to discover new parameters or combinations of parameters that would improve 
diagnosis. (Shelby J. Haberman, who collected the data for a 1976 paper on log-linear 
models, became a distinguished statistician and spent much of his later career at the 
Educational Testing Service in Princeton NJ).
All three datasets are readily available online, and can be easily imported into statisti-
cal programs such as R for use with their built-in machine learning or data mining tools. 
These three datasets, among others, have been used in a rich research literature, almost 
entirely focused on algorithm development. But the authors have not always distin-
guished clearly between technical goals (developing algorithms for classifiers) and actual 
medical use, using terms such as “survival prediction” or “diagnosis” without qualifica-
tion. This distinction is understandably, not discussed in Brownlee’s book, or in most 
other texts on machine learning for that matter.
The differences in scale between an engineering study on algorithm development and 
a developing a classifier or other mathematical model that is suitable for use in medical 
practice can be very large.
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For example, in cardiology, physicians would need more than a binary classification 
of a patient as having or not having CAD. Their needs include assessing patients who 
present with symptoms of stable ischemic heart disease, assessing the extent of the dis-
ease, if any, estimating the risk of sudden cardiac death, or choosing optimal treatment 
strategies. Without strong clinical evidence, few doctors would use a classifier based on 
clinical indications in lieu of conventional diagnostic methods for detection of CAD, for 
example coronary CT angiography.
A more plausible use of a classifier would be to calculate pre-test probability to de-
select patients from expensive tests that they are unlikely to benefit from. That also 
would require well controlled clinical studies to justify its use, and it seems that few such 
studies have been done with classifier based tests. A 2017 systematic review [9] con-
cluded that mathematical models for pre-test prediction of outcomes of tests for sta-
ble CAD in cardiology had “only modest success”. No machine learning-based models 
met the inclusion criteria for acceptance in that review A 2017 study by Korley et  al. 
[10] assessed use of clinical risk factors (such as in the Z-Aldesani database) for diag-
nosing CAD as a pre-test selection tool. That study derived a classifier used a regular-
ized regression method, based on a derivation set of 679 patents to train and validate a 
classifier, with additional validation on 1056 patients from a different cohort. The inves-
tigators concluded that “clinical risk factors, either individually or in combination, are 
insufficient for accurately identifying suspected ACS (acute coronary symptom) patients 
harboring undiagnosed significant coronary artery disease.” The possibility exists, how-
ever, that an improved classifier after proper validation might prove more successful.
Estimating prognosis for survival from breast cancer is important in treatment plan-
ning and for patient information. A recent model, based on a Cox proportional hazard 
model, is currently used for estimating prognosis of breast cancer patients after surgery 
(Wishart et al. 2010 [11]). The model was developed from a cohort of 5694 women who 
had surgery for invasive breast cancer, and validated using an independent data set of 
5468 patients from another medical center. One particular use of this model is to assess 
probable benefits to a patient from adjuvant therapy.
Overall, the contribution of machine learning or data mining to medical diagnosis to 
date has been mixed. In their recent systematic review of the development of risk predic-
tion models from electronic health records data, Goldstein et al. [12] noted the potential 
usefulness of such studies, but also considered areas in which improvement is needed. 
These include the need for studies to validate their results across different healthcare 
centers, develop better methods to deal with missing data, and assessing how the algo-
rithms impact clinical decision making.
In a recent tutorial [13] Goldstein et al. describe the use of machine learning to predict 
risk of death in patients admitted to an emergency after sudden myocardial infarction, 
using electronic health records of 1944 patients—a data set that is nearly seven times 
larger than the Z-Alizadehsani dataset [7] but not out of range of many biomedical engi-
neering groups. The authors conclude that machine learning methods “can be employed 
to help confront issues of multiple and correlated predictors, non-linear relationships, 
and interactions between predictors and endpoints, in large datasets. However, when 
using machine-learning methods, extra care is needed in the form of model valida-
tion.” The authors recommended a series of practical steps to improve the reliability 
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of machine learning models, and stress the need to test the full range of the modeling 
process including variable selection. Similar cautionary advice was given by Cruz and 
Wishart in their 2006 review of the applications of machine learning to estimating can-
cer prognosis [14]. They noted that “it is clear that machine learning methods can be 
used to substantially (15–25%) improve the accuracy of predicting cancer susceptibility, 
recurrence and mortality” but they also complained that “a number of published studies 
also appear to lack an appropriate level of validation or testing.”
All this calls for more extensive validation of classifiers than engineers would typically 
contemplate when developing machine learning algorithms. Moreover, evaluation stud-
ies should be done in concordance with professional recommendations for conducting 
and reporting machine learning studies for predictive use in medicine (e.g. Luo et  al. 
2016 [15]). This requires a higher level of sophistication than can be gained from Brown-
lee’s otherwise excellent book. For soon-to-be biomedical engineers just entering the 
field, this book is a useful beginning but they will need to know much more about how 
to make technology work in medicine [16].
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Appendix
To illustrate potential problems in applying machine learning methods to biomedical 
data sets, a series of calculations were done using the Haberman data set [17] (supple-
mentary material). The data set contains 306 cases, women who had undergone surgery 
for breast cancer between 1958 and 1970 at the University of Chicago’s Billings Hospi-
tal [18]. It has three features (year of operation, age of patient at time of diagnosis, and 
number of nodes) and two classes (patient alive or dead 5 years after surgery)
Additional file
Additional file 1. Examples that illustrate potential problems with machine learning.
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The Haberman data set [17] has no present day medical value for estimating progno-
sis, since it lacks important information such as tumor grade, hormone sensitivity, or 
description of adjuvant therapy. Moreover, it has far too few features to permit effective 
use of some methods in machine learning such as pruning of decision trees. However, it 
provides a simple test case for discussions of machine learning (e.g. https://www.kaggle.
com/gilsousa/haberman-s-survival).
For this Appendix, the data set was randomly divided into a learning set comprising 2/3 
of the complete data (204 cases) and a test set with the remaining 102 cases. Classifiers 
were trained and validated using three algorithms in the Matlab Statistical Toolbox (sup-
port vector machine (SVM), pruned decision trees and naive Bayes classifier). For each 
algorithm, this process was repeated 1000 times using randomly chosen training and test 
sets from the dataset. There was no attempt to address problems arising from the signifi-
cant imbalance in the data set (66% of the patients were still alive 5 years after surgery).
Table  1 summarizes the results for 3 different classifiers, applied repeatedly to the 
dataset 1000 times. The mean accuracy of all three classifiers ranged from 67.6% for the 
Naïve Bayes classifier to 73–74.7% for the other two classifiers (Fig. 1). This performance 
was not impressive, in part because of the very small number of attributes, but neverthe-
less was considerably better than one could get by assigning outcomes by chance (50% 
accuracy).
Table 1 Summary of the mean, minimum and maximum values of accuracy for 1000 draw-
ings of data for the learning and test vector for various classifiers
Type of classifier Min (ACC) Mean (ACC) Max (ACC)
Support vector machine (SVM) 60 73.0 84
Pruned decision tree 53 67.6 79
Naive Bayes classifier 62 74.7 86
Fig. 2 Distribution of ages at time of operation vs. status after 5 years
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A closer look at the data set shows that, while the two classes have very similar char-
acteristics (Table  2), the age distributions have subtle differences, particularly at their 
ends  (Fig.  2). A calculation of 5-year survival probability from the dataset (Table  3) 
shows that the 5-year survival of the older women was lower than for younger patients, 
although the differences were small and perhaps not statistically significant (Table 3). By 
contrast, the number of tumor nodes among the 5-year survivors at time of surgery was 
slightly higher than among the decedents (2.8 vs. 2.0), which is in the unexpected direc-
tion. However, the distribution of this attribute was about the same for both groups, and 
this attribute contributed little to the training of the classifiers. 
We conclude that the classifiers are training chiefly on small differences in the age dis-
tribution in survivors vs. decedents, particularly at the ends of the distributions. This is 
likely to make the results very fragile, i.e. difficult to replicate with different data sets.
The medical significance of these classifiers with that data set are unclear. A higher 
5-year mortality among the older women may result from a greater vulnerability to the 
disease or to complications of treatment. Or it may reflect a higher noncancer mortality 
rate in the older women. Apart from choosing younger patients, it is difficult to envision 
how physicans could use these results to improve treatment of their patients.
The above discussion shows the need to consider both the mechanics of developing 
classifiers, as well as the medical context and requirements for their use. Students read-
ing Brownlee’s fine book will get a feeling for the first of these, but they need a sophisti-
cated understanding of the second as well.
Table 2 Characteristics of subjects in Haberman data set
Class 1 (patient alive 5 years 
after operation) (n = 204)
(mean ± S.D.)
Class 2 (patient died 




Mean date of operation Aug. 1962 ± 3.2 years Aug. 1962 ± 3.3 years
Patient age at time of operation 
(mean ± S.D.)
52.0 ± 11.0 53.7 ± 10.2 0.19
Number of nodes (mean ± S.D.) 2.8 ± 5.9 2.0 ± 9.2 0.36
Table 3 Probabilty of 5-year survival as function of age at time of surgery (from Haberman 
data set)
Age range Subjects Alive after 5 years Probability alive 
at 5 years
30–34 14 12 0.86
35–39 26 24 0.92
40–44 40 28 0.70
45–49 44 29 0.66
50–54 56 38 0.68
55–59 43 35 0.81
60–64 35 26 0.74
65–69 27 18 0.67
70–74 16 12 0.75
75–79 4 3 0.75
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